Clinical Trials Browser

Pathologic Complete Response × 1 year × Clear all

NCT06694454 2026-05-27

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Phase 1/2 Recruiting

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

NCT07586813 2026-05-14

N01-A-PICIT-GI

Phase 2 Recruiting

Classical hematologyGastrointestinal

Pathologic Complete Response, Digestive System Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Thrombocytopenia, Colorectal Neoplasms

NCT07586826 2026-05-14

N01-A-PICIT-GT

Phase 2 Recruiting

BreastClassical hematologyGynecologicThoracic

Pathologic Complete Response, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Thrombocytopenia, Endometrial Neoplasms

NCT01042379 2026-05-06

I-SPY

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT06743555 2026-04-28

SAVED LUNG

Phase 1 Not yet recruiting

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

NCT07538206 2026-04-20

Vebectotamab Vedotin Combined With Pucotelimab in the Treatment of Locally Advanced Laryngeal Carcinoma

Phase 1/2 Not yet recruiting

Pathologic Complete Response, Head and Neck Neoplasms

NCT07472868 2026-03-16

MEND-IT II

Phase 3 Not yet recruiting

Pathologic Complete Response

NCT05926024 2026-03-11

Long-Term Follow-Up in Women With Early Breast Cancer Three Years of More Post Primary Treatment

Active not recruiting

Pathologic Complete Response, Breast Neoplasms

NCT06647680 2026-03-06

Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）

Phase 2 Recruiting

Gastrointestinal

Pathologic Complete Response, Rectal Neoplasms

NCT03832569 2026-03-05

Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors

Phase EARLY_PHASE1 Active not recruiting

Pathologic Complete Response

NCT06130995 2026-03-05

Relugolix + Enzalutamide Study in High-Risk Prostate Cancer

Phase 1 Recruiting

Pathologic Complete Response, Neoplasm, Residual

NCT04055220 2026-02-17

REGOSTA

Phase NA Recruiting

Pathologic Complete Response, Bone Neoplasms, Chondrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Patient Compliance, Sarcoma, Ewing, Osteosarcoma, Histiocytoma, Malignant Fibrous

NCT07397442 2026-02-11

Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer

Phase 2 Not yet recruiting

Gastrointestinal

Pathologic Complete Response, Rectal Neoplasms

NCT07353723 2026-01-20

Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer

Phase 2 Recruiting

Pathologic Complete Response, Head and Neck Neoplasms

NCT07353840 2026-01-20

T-START-CR

Pathologic Complete Response, Lymphoma, T-Cell, Peripheral

NCT07328841 2026-01-09

Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy

Phase 3 Recruiting

Nasopharyngeal Carcinoma, Pathologic Complete Response

NCT07328854 2026-01-09

40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma

Phase 3 Recruiting

Nasopharyngeal Carcinoma, Pathologic Complete Response

NCT06364371 2025-12-18

Dynamic Multi-omics Integration Model to Predict Neoadjuvant Therapy Response in Locally Advanced Rectal Cancer

Pathologic Complete Response

NCT01794572 2025-12-12

TOMMY

Phase NA Terminated

13 enrolled 10 charts

Pathologic Complete Response, Multiple Myeloma, Recurrence

NCT01844986 2025-12-10

SOLO-1

Phase 3 Active not recruiting

450 enrolled 18 charts 1 FDA

Pathologic Complete Response, Ovarian Neoplasms

NCT07007052 2025-11-26

TAGVEN

Phase 2 Not yet recruiting

Pathologic Complete Response, Blastic Plasmacytoid Dendritic Cell Neoplasm

NCT07066189 2025-10-29

Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBC

Phase NA Recruiting

Pathologic Complete Response, Motor Activity, Triple Negative Breast Neoplasms

NCT04229979 2025-10-01

REGAL

Phase 3 Active not recruiting

Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT04335669 2025-09-12

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

Phase 3 Active not recruiting

Pathologic Complete Response, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07164872 2025-09-10

Neoadjuvant Chemotherapy Combined With Preoperative Radiotherapy for Locally Advanced Breast Cancer

Phase NA Not yet recruiting

Pathologic Complete Response, Breast Neoplasms

NCT07166185 2025-09-10

NEOTRAPSCAL

Pathologic Complete Response, Breast Neoplasms

NCT06087718 2025-08-14

Feasibility of the Maastro Applicator in Rectal Cancer

Phase NA Active not recruiting

Gastrointestinal

Pathologic Complete Response, Radiation Injuries, Rectal Neoplasms

NCT06728982 2025-08-01

Impact Of Metformin In Rectal Cancer Patients

Phase 2/3 Completed

Pathologic Complete Response

NCT01757535 2025-07-08

QUAZAR AML-001

Phase 3 Completed

472 enrolled 24 charts 1 FDA

Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT06811844 2025-07-01

Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC

Phase 2 Recruiting

Pathologic Complete Response, Nasopharyngeal Neoplasms

NCT03522246 2025-06-24

ATHENA

Phase 3 Active not recruiting

1,097 enrolled 26 charts

Carcinoma, Ovarian Epithelial, Pathologic Complete Response, Fallopian Tube Neoplasms, Neoplasms

NCT06927180 2025-06-23

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms